Tempest Therapeutics, Inc. (TPST): Nasdaq/NYSE listing notice — Tempest Therapeutics warned by Nasdaq for low equity and board independence; two directors resign
Tempest Therapeutics, Inc.
Stockholders' equity of $822k vs Nasdaq's $2.5M minimum; 45 days to submit compliance plan by July 6, 2026.
Directors Michael Raab and Christine Pellizzari resigned, causing non-compliance with majority independence and committee rules.
Company not eligible for standard cure period due to multiple vacancies; must submit plan for board compliance within 45 days.
Both deficiencies have no immediate listing effect but risk delisting if plans rejected or compliance not achieved.
Tempest Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding board independence.
Exchange
nasdaq
Notice
noncompliance notice
Deficiency
board independence
Exact text from the filing
May 22, 2026, Tempest Therapeutics, Inc. (the “Company”) notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company will not be in compliance with the majority independent director requirement under Nasdaq Listing
Tempest Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
Exchange
nasdaq
Notice
deficiency notice
Deficiency
stockholders equity
Rules
5550(b)(1)
Exact text from the filing
May 19, 2026, Tempest Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.